• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

作者信息

Messori Andrea, Peyvandi Flora, Trippoli Sabrina, Palla Roberta, Rosendaal Frits R, Mannucci Pier Mannuccio

机构信息

HTA Unit, ESTAR, Regional Health Service, Florence, Italy.

"A. Bianchi Bonomi" Haemophilia and Thrombosis Centre, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico" and Luigi Villa" Foundation, Milan, Italy.

出版信息

Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22.

DOI:10.2450/2017.0253-17
PMID:29328904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6343594/
Abstract
摘要

相似文献

1
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".对“在接受重组或血浆源性凝血因子VIII治疗的既往未治疗的重度A型血友病患者中高滴度抑制剂：预算影响分析”的进一步评论
Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22.
2
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.对梅索里等人《接受重组或血浆源性凝血因子 VIII 治疗的既往未治疗的重度甲型血友病患者中的高滴度抑制剂：预算影响分析》一文的回复
Blood Transfus. 2019 Jan;17(1):85. doi: 10.2450/2017.0160-17. Epub 2017 Oct 3.
3
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.在接受重组或血浆源性凝血因子VIII治疗的既往未治疗的重度甲型血友病患者中高滴度抑制剂：预算影响分析
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
4
Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.
Haemophilia. 2017 Mar;23(2):e87-e92. doi: 10.1111/hae.13193. Epub 2017 Feb 20.
5
Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.评价低滴度抑制剂或有抑制剂个人史的血友病 A 患者接受因子 VIII 治疗的安全性和有效性。患者数据 rAFH-PFM 上市后安全性研究的荟萃分析。
Thromb Haemost. 2015 Jul;114(1):56-64. doi: 10.1160/TH14-10-0882. Epub 2015 May 28.
6
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.在未曾接受治疗的重度 A 型血友病患者中，重组凝血因子 VIII 产品与抑制剂的发展：三项研究的联合分析。
Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7.
7
Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate : Final report from a prospective study.奥曲肽治疗未治疗过的重度血友病 A 患者的因子 VIII 抑制剂发生率低：前瞻性研究的最终报告。
Haemophilia. 2018 Mar;24(2):221-228. doi: 10.1111/hae.13385. Epub 2018 Jan 3.
8
Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.甲型血友病患者中抑制物的发生率——重组和血浆源性凝血因子VIII浓缩物近期研究综述
Haemophilia. 1999 May;5(3):145-54. doi: 10.1046/j.1365-2516.1999.00300.x.
9
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.用于诱导有抑制剂的重度 A 型血友病患者免疫耐受的重组凝血因子 VIII Fc 融合蛋白：一项回顾性分析。
Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.
10
High-titre factor VIII inhibitor in two children with mild haemophilia A.两名轻度甲型血友病儿童体内的高滴度凝血因子VIII抑制物
Haemophilia. 2001 Mar;7(2):215-9. doi: 10.1046/j.1365-2516.2001.00493.x.

本文引用的文献

1
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.对梅索里等人《接受重组或血浆源性凝血因子 VIII 治疗的既往未治疗的重度甲型血友病患者中的高滴度抑制剂：预算影响分析》一文的回复
Blood Transfus. 2019 Jan;17(1):85. doi: 10.2450/2017.0160-17. Epub 2017 Oct 3.
2
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.在接受重组或血浆源性凝血因子VIII治疗的既往未治疗的重度甲型血友病患者中高滴度抑制剂：预算影响分析
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
3
Impact of inhibitors on hemophilia A mortality in the United States.抑制剂对美国甲型血友病死亡率的影响。
Am J Hematol. 2015 May;90(5):400-5. doi: 10.1002/ajh.23957. Epub 2015 Feb 5.